UPDATE: Wedbush Securities Initiates Regulus Therapeutics at Outperform on Pipeline Progress
Wedbush Securities initiated coverage on Regulus Therapeutics (NASDAQ: RGLS) with an Outperform rating and a $10 price target.
Wedbush Securities noted, "Regulus is developing oligonucleotide drugs that target microRNA, important regulators of gene expression whose dysregulation is implicated in a variety of diseases and disease states. Oligonucleotide drug discovery and development is rapid and predictable as drugs are assembled using the complementary microRNA target as a template, and other oligonucleotide drugs inform ADME, pK, safety and tolerability."
Regulus Therapeutics closed at $4.34 on Wednesday.
Latest Ratings for RGLS
|Jun 2016||BMO Capital||Downgrades||Outperform||Market Perform|
|Jun 2016||Chardan Capital||Maintains||Buy|
|Apr 2016||Chardan Capital||Initiates Coverage on||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.